Sign up


Match Document Document Title
8835394 Treatment for basal cell carcinoma  
The present invention provides a method of treating basal cell carcinoma in a subject. Generally, the method includes administering to the subject an amount of IRM compound effective for treating...
8834876 Therapeutic agent for hematopoietic tumors  
An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as w...
8828417 Bioactive coating for an implantable device or bioprosthesis  
For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts,...
8828391 Method for EGFR directed combination treatment of non-small cell lung cancer  
The present invention relates to a method of treating patients suffering from cancers driven by deregulated Human Epidermal Growth Factor Receptor (HER/Human EGFR), wherein an irreversible tyrosine...
8828381 Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas  
A method for enhancing the therapeutic effect of cytokine treatment is disclosed. More specifically the present invention relates to a method for administering to a tumor patient a therapeutic dose...
8828685 Monomeric forms of human aminoacyl-t-RNA synthetases having non-canonical biological activities  
Isolated monomelic aminoacyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.
8828944 Compounds and uses thereof to induce an immunogenic cancer cell death in a subject  
The present invention relates to the fields of genetics, immunology and medicine. The present invention more specifically relates to in vitro or ex vivo methods for determining the susceptibility...
8828957 Methods for generating immunity to antigen  
Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vectors comprises a...
8822442 Somatostatin-dopamine chimeric analogs  
The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
8821883 Method of treating B cell cancers by administering truncated BAFF receptors  
The disclosure provides a non-naturally occurring BAFF-R glycoprotein having a deletion in the extracellular domain which results in an altered O-linked glycosylation pattern. The disclosure also...
8822421 E2F as a target of hormone refractory prostate cancer  
The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also...
8821872 Identification and characterization of a specific CCK-C receptor antibody for human pancreatic cancer and its use for early detection and staging of pancreatic cancer  
Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this...
8822419 Membrane resident peptide in anti-cancer peptides causes tumor cell necrosis rather than apoptosis of cancer cells  
An aspect of the invention provides a method of selectively necrosing cells, comprising: providing a plurality cells, including at least one cancer cell and at least one non-cancerous cell; and...
8822420 Peptides and aptamers thereof as specific modulators of mutant p53 function  
In the present application isolated peptides and aptamers thereof able to interact with structural and conformational p53 mutants within the region of the wild-type p53 DNA binding core domain...
8822422 Antitumor agent  
An antitumor agent containing, in combination, at least one kind of antitumor agent selected from the group consisting of an antitumor agent that forms a cross-link with DNA and shows an antitumor...
8821867 4-1BB binding molecules  
The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic...
8815804 Methods and compositions related to targeting tumors and wounds  
Disclosed are compositions and methods useful for targeting tumors, sites of injury and blood clots. The compositions and methods are based on peptide sequences that selectively bind to and home to...
8815805 Formulations having an antagonist of α5β1 for anti-angiogenesis and cancer treatment  
The teachings provided herein generally relate to a combination therapy and are directed to pharmaceutical compositions and methods for administering a combination of an α5β1 antagonist with an α...
8809280 Therapeutic peptides  
The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted β amino acid, each of the ...
8808698 Methods for inhibition of lymphangiogenesis and tumor metastasis  
The present invention is directed to compositions and methods for inhibiting the development of new lymphatic vessels, and for inhibiting tumor cell dissemination through the lymphatics. In...
8802627 Fusion protein composed of matrix metalloproteinase-2 inhibitor peptide derived from amyloid-B precursor protein and tissue inhibitor of metalloproteinase-2  
The present invention provides an agent capable of inhibiting MMP-2 specifically. Disclosed is a fusion molecule composed of a β-amyloid precursor protein molecule-derived domain having an ...
8802153 System for targeted delivery of therapeutic agents  
The present invention provides a drug delivery system for targeted delivery of therapeutic agent-containing particles to tissues, cells, and intracellular compartments. The invention provides...
8802635 Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof  
Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such...
8802632 Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof  
Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a...
8802631 Peptides and methods for the treatment of gliomas and other cancers  
The invention is based on the discovery that STM/Hop promotes proliferation of human glioblastoma-derived cells but not of normal astrocytes and that the proliferation requires the binding of...
8802634 CD40-L Inhibitory Peptides  
The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native...
8802618 Controlled modulation of amino acid side chain length of peptide antigens  
The invention provides a method for the creation of peptide antigens comprising epitopes with at least a first modification comprising a shortened or lengthened amino acid side chain. By extension...
8796220 Vaccine for the prevention of the recurrence HER2/neu expressing cancer  
The invention features methods to induce and maintain a protective cytotoxic T-lymphocyte response to a peptide of the HER2/neu oncogene, E75, with the effect of inducing and maintaining protective...
8796426 Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart  
The present invention relates to a combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart and...
8796219 Target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds and use thereof  
The present invention relates to a target-activated cell/tissue-penetrating peptide for delivery of impermeable compounds (Target Activated Cell/tissue Translocation peptide for Impermeable...
8795627 Treatment of liver disorders by administration of RAP conjugates  
The present invention relates to the use of receptor-associate protein (RAP) and fragments and variants thereof to improve delivery of therapeutic compounds to the liver and provides methods to...
8796218 Complex and production process  
A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of α-lactalbumin, such as human α-lactalbumin or a fragment thereof but w...
8791073 Peptide-modified polyurethane compositions and associated methods  
Peptide-modified polyurethanes comprising the reaction product of an isocyanate, a chain extender, and a peptide are provided. Also provided processes for making a peptide-modified polyurethane...
8791285 Activatable nanoprobes for intracellular drug delivery  
An activatable nanoprobe is provided having a core component and an active agent associated with the core component via a bond configured to be cleaved upon exposure to an endogenous compound.
8791076 Agonists of neurotrophin receptors and their use as medicaments  
The invention relates to compounds of Formula I: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, and R3 are defined as set forth in the specification. The compounds are...
8791075 Methods and compositions for inhibition of BCL6 repression  
The invention is directed to a compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove. The present invention is further directed to methods for...
8791074 Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors  
The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by...
8784811 Method of treating cancer using antibodies to a non-ligand binding region of NOTCH1  
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis,...
8785392 Method for inhibiting cancer metastasis by administration of the extracellular domain DLK1 or a DLK1-FC fusion protein  
A recombinant expression vector, comprising extracellular soluble domain genes of DLK1 and IgG antibody Fc domain genes, is constructed, and DLK1-Fc fusion protein is expressed and purified at 293E...
8784797 Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma  
The present invention relates to methods, pharmaceutical compositions and kits for use in the treatment of Adult T-cell leukemia/lymphoma. More particularly, the present invention relates to a...
8785371 Drug delivery of temozolomide for systemic based treatment of cancer  
The present invention relates to methods of drug delivery for the treatment of a condition or disease, such as cancer. In one embodiment, the invention provides a method of preparing a...
8785373 Agents capable of downregulating an MSF-A-dependent HIF-1alpha and use thereof in cancer treatment  
Methods and pharmaceutical compositions for the treatment of cancer or acute ischemia are provided. Also provided are methods of identifying agents capable of preventing the formation of or...
8785395 Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases  
The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that...
8778879 Homogeneous vaccine composition comprising a conjugate of EGF and P64K for the treatment of tumors  
The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on...
8778350 Method of treating cancer with an HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same  
Disclosed are: a peptide comprising an amino acid sequence composed of contiguous nine amino acid residues derived from a WT1 protein, wherein an amino acid residue at position 2 in the amino acid...
8779092 Metastasis-specific peptides and their diagnostic and therapeutic applications  
The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as...
8772445 Production and use of antitumoral cyclodepsipeptides  
A compound having the general structure R1, R2, R3 and R4 being selected from the group consisting of a hydrogen atom (H) and a C1-C20 alkyl, and R5 being a phenyl radical.
8772243 Methods for predicting the response to anti-cancer treatment with an agonist of TLR7 or an agonist of TLR8  
The present invention relates to methods for predicting the response to treatment with an agonist of TLR7, or an agonist of TLR8 or an anti-cancer agent for treating cancer, in particular non-small...
8771691 Methods for the treatment and the prognostic assessment of malignant pleural mesothelioma  
The present invention relates to methods for the treatment and the prognostic assessment of malignant pleural mesothelioma.
8772244 Tubulin inhibitors  
The present invention relates to novel tubulin binding molecules of formula (I) and their use for the treatment of cancer and other diseases.